Seres Therapeutics Inc (NAS:MCRB)
$ 0.915 0.038 (4.33%) Market Cap: 156.22 Mil Enterprise Value: 176.53 Mil PE Ratio: 0 PB Ratio: 6.54 GF Score: 47/100

Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 01:15PM GMT
Release Date Price: $7.78 (-3.47%)
Unidentified Analyst

Good morning, and thank you for joining us today. My name is [Malika], and I am an associate in JPMorgan's health care group.

Before I introduce you to our presenters today, I want to call your attention to the blue button on your screen. This is where you will submit questions that will be addressed during Q&A.

With that, I am pleased to introduce you to Eric Shaff, CEO; Carlo Tanzi, Investor Relations; David Ege, Chief Technology Officer; Matt Henn, Chief Scientific Officer; Lisa von Moltke, Chief Marketing Officer; Terri Young, Chief Commercial and Strategy Officer; and David Arkowitz, Chief Financial Officer at Seres Therapeutics. I know that they are all very excited to tell you about their story, so we'll turn it over to Eric and his team.

Eric D. Shaff
Seres Therapeutics, Inc. - President, CEO & Director

Well, good morning, everybody. And let me start by saying, I hope everyone on the line is healthy and well, and we look forward to speaking together in person, hopefully soon.

Thank you to [Malika] and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot